AgentsTafasitamab (anti-CD19) + lenalidomide

BackboneAdded to frontline R-CHOP

EfficacyPFS HR 0.75 (8.2% at 2y)

CaveatOS not yet mature

PositiveNot yet

frontMIND

S101 · Lenz · plenary · 899 patients

• Tafasitamab + lenalidomide added to R-CHOP vs R-CHOP, frontline high-risk DLBCL/HGBL
• PFS HR 0.75 (0.59 to 0.96), P=0.019
• Absolute 2-year PFS gain about 8.2%
• Overall survival immature (interim HR 0.85), final analysis planned at 5 years

Why it matters: The first frontline regimen to improve on R-CHOP since rituximab, but mature OS and cost-effectiveness will shape adoption.

Early phasePhase 1

LB2501

In vivo CD19/CD20 dual CAR-T · relapsed/refractory B-cell NHL · Fan

• Delivered in vivo, avoiding apheresis and weeks of manufacturing
• Median time from consent to infusion 17.5 days
• At the higher dose (n=6): 100% overall response, 83.3% complete
• CRS grade 1 to 2 only; no ICANS and no dose-limiting toxicity

Why it matters: Proof of concept for off-the-shelf, single-infusion CAR-T without lymphodepletion, though the numbers are very small.

A frontline win still needs mature survival data before it changes the standard.frontMIND improved PFS but overall survival is not yet mature.